© 1993 by European Society of Cardiology
Copyright © 1993, European Society of Cardiology
The endothelin-1 receptor antagonist BQ-123 reduces infarct size in a canine model of coronary occlusion and reperfusion
Department of Pharmacology, Bristol-Myers Squibb Pharmaceutical Research Institute, PO Box 4000, Princeton, NJ 08543-4000, USA: G J Grover, S Dzwonczyk, C S Parham.
Correspondence to Dr Grover.
Objective: The aim was to determine the effect of the endothelin-1 receptor antagonist, BQ-123, on infarct size in anaesthetised dogs subjected to 90 min of left circumflex coronary artery occlusion and 5 h of reperfusion. Methods: BQ-123 was given directly into the left circumflex coronary artery at 0.03 or 10 µg·kg–1·min–1 starting 15 min before coronary occlusion and continuing throughout occlusion and reperfusion. Regional myocardial blood flow was determined before, during, and after ischaemia. At the end of the study, infarct size was determined using triphenyltetrazolium chloride staining. Results: Myocardial infarct size was significantly reduced by BQ-123 (40% reduction from vehicle infarct size) at both doses used. This cardioprotection occurred despite a lack of effect of BQ-123 on peripheral haemodynamic status. BQ-123 also had no effect on regional myocardial blood flow in ischaemic and non-ischaemic tissue. Both cardioprotective doses of BQ-123 were found to completely abolish the coronary constrictor effect of intracoronary endothelin-1 administration. Conclusions: These data indicate that endothelin-1 release during ischaemia may be involved in the pathogenesis of myocardial ischaemia and infarction.
Cardiovascular Research 1993;27:1613-1618
KEYWORDS endothelin-1; BQ-123; infarct size; dog; coronary occlusion
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  G. F. Merrill, T. H. Rork, N. M. Spiler, and R. Golfetti Acetaminophen and myocardial infarction in dogs Am J Physiol Heart Circ Physiol, November 1, 2004; 287(5): H1913 - H1920. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. Xia and M. Karmazyn Obligatory Role for Endogenous Endothelin in Mediating the Hypertrophic Effects of Phenylephrine and Angiotensin II in Neonatal Rat Ventricular Myocytes: Evidence for Two Distinct Mechanisms for Endothelin Regulation J. Pharmacol. Exp. Ther., July 1, 2004; 310(1): 43 - 51. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Q.-D. Wang, J. Pernow, P.-O. Sjoquist, and L. Ryden Pharmacological possibilities for protection against myocardial reperfusion injury Cardiovasc Res, July 1, 2002; 55(1): 25 - 37. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Basso, G. Thiene, M. Della Barbera, A. Angelini, M. Kirchengast, and S. Iliceto Endothelin A-receptor antagonist administration immediately after experimental myocardial infarction with reperfusion does not affect scar healing in dogs Cardiovasc Res, July 1, 2002; 55(1): 113 - 121. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. L. Heaps and D. K. Bowles Gender-specific K+-channel contribution to adenosine-induced relaxation in coronary arterioles J Appl Physiol, February 1, 2002; 92(2): 550 - 558. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. D. Monti, S. Allibardi, P. M. Piatti, G. Valsecchi, S. Costa, G. Pozza, S. Chierchia, and M. Samaja Triglycerides impair postischemic recovery in isolated hearts: roles of endothelin-1 and trimetazidine Am J Physiol Heart Circ Physiol, September 1, 2001; 281(3): H1122 - H1130. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Pernow, A.T. Gonon, and A. Gourine The role of the endothelium for reperfusion injury Eur. Heart J. Suppl., June 1, 2001; 3(suppl_C): C22 - C27. [Abstract] [PDF]
|
|
|
|
 |
|
 L. E. Spieker, G. Noll, F. T. Ruschitzka, and T. F. Luscher Endothelin receptor antagonists in congestive heart failure: a new therapeutic principle for the future? J. Am. Coll. Cardiol., May 1, 2001; 37(6): 1493 - 1505. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. V. Gourine, A. T. Gonon, and J. Pernow Involvement of nitric oxide in cardioprotective effect of endothelin receptor antagonist during ischemia-reperfusion Am J Physiol Heart Circ Physiol, March 1, 2001; 280(3): H1105 - H1112. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. Duru, M. Barton, T. F. Luscher, and R. Candinas Endothelin and cardiac arrhythmias: do endothelin antagonists have a therapeutic potential as antiarrhythmic drugs? Cardiovasc Res, February 1, 2001; 49(2): 272 - 280. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. Galiuto, A. N. DeMaria, U. del Balzo, K. May-Newman, S. F. Flaim, P. L. Wolf, M. Kirchengast, and S. Iliceto Ischemia-Reperfusion Injury at the Microvascular Level : Treatment by Endothelin A-Selective Antagonist and Evaluation by Myocardial Contrast Echocardiography Circulation, December 19, 2000; 102(25): 3111 - 3116. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Z. S. Kyriakides, D. Th. Kremastinos, T. M. Kolettis, A. Tasouli, A. Antoniadis, and D. J. Webb Acute Endothelin-A Receptor Antagonism Prevents Normal Reduction of Myocardial Ischemia on Repeated Balloon Inflations During Angioplasty Circulation, October 17, 2000; 102(16): 1937 - 1943. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Z S Kyriakides, D T Kremastinos, E Bofilis, D Tousoulis, A Antoniadis, and D J Webb Endogenous endothelin maintains coronary artery tone by endothelin type A receptor stimulation in patients undergoing coronary arteriography Heart, August 1, 2000; 84(2): 176 - 182. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Ono, A. Matsumori, T. Shioi, Y. Furukawa, and S. Sasayama Contribution of Endothelin-1 to Myocardial Injury in a Murine Model of Myocarditis : Acute Effects of Bosentan, an Endothelin Receptor Antagonist Circulation, October 26, 1999; 100(17): 1823 - 1829. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
I. Sharif, K. A. Kane, and C. L. Wainwright Endothelin and ischaemic arrhythmias-antiarrhythmic or arrhythmogenic? Cardiovasc Res, September 1, 1998; 39(3): 625 - 632. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Zhang, J. R. Oliver, and J. D. Horowitz Endothelin B receptor-mediated vasoconstriction induced by endothelin A receptor antagonist Cardiovasc Res, September 1, 1998; 39(3): 665 - 673. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. T Gonon, Q.-D. Wang, and J. Pernow The endothelin A receptor antagonist LU 135252 protects the myocardium from neutrophil injury during ischaemia/reperfusion Cardiovasc Res, September 1, 1998; 39(3): 674 - 682. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Szabo, L. Fazekas, S. Bahrle, D. MacDonald, N. Stumpf, C. F Vahl, and S. Hagl Endothelin-A and -B antagonists protect myocardial and endothelial function after ischemia/reperfusion in a rat heart transplantation model Cardiovasc Res, September 1, 1998; 39(3): 683 - 690. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Yamashita, T. Yoshimasa, H. Arai, J. Hiraoka, K. Takaya, Y. Miyamoto, Y. Ogawa, H. Itoh, and K. Nakao Identification of Cis-elements of the Human Endothelin-A Receptor Gene and Inhibition of the Gene Expression by the Decoy Strategy J. Biol. Chem., June 26, 1998; 273(26): 15993 - 15999. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Ergul, K. Shoemaker, D. Puett, and R. L. Tackett Gender Differences in the Expression of Endothelin Receptors in Human Saphenous Veins In Vitro J. Pharmacol. Exp. Ther., May 1, 1998; 285(2): 511 - 517. [Abstract] [Full Text]
|
|
|
|
 |
|
 W. F. Baker JR Thrombosis and Hemostasis in Cardiology: Review of Pathophysiology and Clinical Practice (Part I) Clinical and Applied Thrombosis/Hemostasis, January 1, 1998; 4(1): 51 - 75. [Abstract] [PDF]
|
|
|
|
 |
|
 C. R. Aversa, S. Oparil, J. Caro, H. Li, S.-D. Sun, Y.-F. Chen, M. R. Swerdel, T. M. Monticello, S. K. Durham, A. Minchenko, et al. Hypoxia stimulates human preproendothelin-1 promoter activity in transgenic mice Am J Physiol Lung Cell Mol Physiol, October 1, 1997; 273(4): L848 - L855. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. E. Donckier, P.-E. Massart, D. Hodeige, H. Van Mechelen, J.-P. Clozel, O. Laloux, J.-M. Ketelslegers, A. A. Charlier, and G. R. Heyndrickx Additional Hypotensive Effect of Endothelin-1 Receptor Antagonism in Hypertensive Dogs Under Angiotensin-Converting Enzyme Inhibition Circulation, August 19, 1997; 96(4): 1250 - 1256. [Abstract] [Full Text]
|
|
|
|
|
|
J. Pernow and Q.-D. Wang Endothelin in myocardial ischaemia and reperfusion Cardiovasc Res, March 1, 1997; 33(3): 518 - 526. [Abstract] [PDF]
|
|
|
|
|
|
H. Shimoyama, H. N. Sabbah, S. Borzak, M. Tanimura, S. Shevlyagin, G. Scicli, and S. Goldstein Short-term Hemodynamic Effects of Endothelin Receptor Blockade in Dogs With Chronic Heart Failure Circulation, August 15, 1996; 94(4): 779 - 784. [Abstract] [Full Text]
|
|
|
|
 |
|
 E. R. Levin Endothelins N. Engl. J. Med., August 10, 1995; 333(6): 356 - 363. [Full Text] [PDF]
|
|
|
|
 |
|
 T. Tonnessen, A. Giaid, D. Saleh, P. A. Naess, M. Yanagisawa, and G. Christensen Increased In Vivo Expression and Production of Endothelin-1 by Porcine Cardiomyocytes Subjected to Ischemia Circ. Res., May 1, 1995; 76(5): 767 - 772. [Abstract] [Full Text]
|
|